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Results: From 337 patients finally undergoing the planned procedure, 307 patients from 7
out of 8 sites could be followed-up (91%). Baseline parameters were identical in both
groups, 2.2±0.6 vessels were treated in CABG patients, while 1.9±0.5 vessels were
treated in PTCA patients. 37% of surgical patients received internal mammary artery
grafts, while no stents were used in patients undergoing PTCA. At the end of the
13.6±1.5 year follow-up period, degree of angina, degree of dyspnoe and utilization of
nitrates were identical in both groups. With a total number of 76 deaths, Kaplan-Meyer
analysis revealed a comparable mortality distribution in both groups. The time to first
reintervention was significantly shorter in patients undergoing PTCA, p<0.001. While the
number of reinterventions (CABG = 97, PTCA = 139, ns) and crossover rates (CABG to
PTCA = 50, PTCA to CABG = 53, ns) were comparable in both groups, distribution was
distinctly different with more early interventions in patients assigned to PTCA.
Conclusion: The results of our 13.6-year follow-up suggest that in patients with symptom-
atic multivessel disease, both PTCA and CABG are associated with a comparable long-
term survival and symptomatic efficacy. In how far these results may be altered by devel-
opments such as drug eluting stents or new surgical techniques remains to be deter-
mined.
1138-43 Relationship of Obesity to Target Vessel 
Revascularization and Other Outcomes Following 
Coronary Stenting: Observations From the TARGET 
Trial
Jack L. Martin, Timothy A. Shapiro, Seth S. Martin, Howard C. Herrmann, Gang Jia, 
Peter M. DiBattiste, David J. Moliterno, Main Line Health, Bryn Mawr, PA, Cleveland 
Clinic, Cleveland, OH
Background: Prior studies reporting improved outcomes for obese patients (pts) follow-
ing percutaneous coronary intervention (PCI) had variable stent and glycoprotein IIbIIIa
inhibitor (GPI) use and did not report target vessel revascularization (TVR).
Methods: The TARGET trial compared short and long-term outcomes of pts randomized
to receive tirofiban or abciximab for intent-to-stent PCI.
Results: 36% of 4,789 pts were obese (body-mass index [BMI] >30). Obese pts were
younger (59±11 vs. 63.7±11 years, p<0.001), with more females (30 vs. 24%, p<0.001)
and diabetics (33 vs. 18%, p<0.001). Major bleeding was lower in the obese (0.4 vs.
1.1%, p<0.02). Obese and non-obese pts had a similar incidence of 30-day death, myo-
cardial infarction and urgent TVR (6.8 vs. 7.5%, p=ns). Death and myocardial infarction at
6 months were also similar (8.2 vs. 7.9%, p=ns). There was a “U” shaped relationship
between BMI and TVR with higher TVR in pts in the highest quartile (>32) of BMI (11 vs.
9%, p<0.01) particularly in pts <age 65 (12 vs. 8%, p=0.003). TVR in low BMI pts was not
significantly different in this small cohort compared to other pts. Excluding diabetics, the
“U” shaped relationship persisted with a trend to higher TVR in pts < age 65 with BMI >32
(11 vs. 8.0%, p=0.098).
Conclusion: Obese pts have significantly higher TVR after coronary stenting. Obese pts,
although younger, do not have fewer short or long-term ischemic events following PCI
with routine use of GPI and stents. The obese have a lower incidence of major bleeding.
1138-44 Platelet Glycoprotein IIIa Genotype Is Not a Risk Factor 
for Target Vessel Revascularization Following 
Percutaneous Coronary Intervention
Laxmi S. Mehta, Kimberly A. Skelding, Demetri Demetrious, Mark Emerick, Judith Boura, 
James A. Goldstein, William W. O'Neill, William Beaumont Hospital, Royal Oak, MI
Background: The platelet glycoprotein IIIa polymorphism has been shown to be associ-
ated with an increased risk for restenosis post–percutaneous coronary intervention (PCI)
in one prior study. The IIIa component of this complex has a known genetic polymor-
phism (PLA) with 2 known alleles A1 and A2. We sought to delineate whether PLA2 is an
independent risk factor for target vessel revascularization (TVR) following PCI.
Methods: We prospectively analyzed the PLA genotype through peripheral blood sam-
pling in 553 patients undergoing PCI at William Beaumont Hospital, Royal Oak, Michi-
gan. Clinical variables were collected at baseline and follow-up was performed by
telephone contact. Patients or family members were queried with regard to TVR, myocar-
dial infarction (MI) and death at 2 years.
Results: The A2/A2 genotype was present in only 14 patients (2%), A1/A2 was present in
131 patients (24%) and A1/A1 in 408 patients (74%). There was no difference within the
groups A2/A2, A1/A2, and A1/A1 in terms of age (64+9 vs 66+11 vs 64+11, p=0.52) or
female gender (21% vs 25% vs 27%, p=0.84). No difference was seen in clinical history
of smoking, hyperlipidemia, hypertension, diabetes or stroke. The LAD was more com-
monly the target vessel in the A2/A2 group (50% vs 25% vs 38%, p=0.016). No difference
was seen between the groups in terms of treatment with angioplasty (14% vs 25% vs
25%, p=0.66) or stent (86% vs 70% vs 70%, p=0.46). TVR was identified in 15%, 22%,
and 20% of the patients respectively (p=0.86). The combined endpoint of TVR, MI or
death was identified in 21%, 31%, and 24% of the patients respectively at 2 years
(p=0.33).
Conclusions: PLA polymorphisms are not predictive of TVR or the combined endpoint
of TVR, MI or death.
1138-45 Eliminating Angina Enhances Patients' Return to Work 
After Percutaneous Coronary Interventon
Avinash Khanna, Hussam Abu-Issa, John A. House, Steven P. Marso, John A. Spertus, 
University of Missouri - Kansas City, Kansas City, MO
Background: Returning to work after revascularization is a meaningful clinical outcome
to both patients and society. Yet factors influencing patients' return to work after percuta-
neous coronary intervention (PCI) have not been thoroughly investigated. We evaluated
baseline and 1-year patient characteristics associated with returning to work after PCI.
Methods: We prospectively followed 1,360 patients undergoing PCI from February 1998
to August 2000. Data was obtained at baseline and at one year. 489 patients were work-
ing at baseline and were the focus of this analysis. The effect of demographics (age, sex,
marital status), medical comorbidities (peripheral vascular disease, cerebrovascular dis-
ease, congestive heart failure, renal dysfunction), disease severity (angina frequency,
number of diseased vessels), and health status (both baseline and at 1 year using the
Seattle Angina Questionnaire (SAQ)) were examined. SAQ is a disease specific function
tool where higher scores are reflective of better health status (better function, less
angina, and less physical limitation). Multivariable logistic regression modeling was used
to define independent predictors of returning to paid employment.
Results: At 1-year follow-up 297 (83%) of the 355 patients working at baseline ( 73% of
the original cohort on whom follow-up was available) were still working. The independent
predictors of returning to work, from the final multivariable model, were: age <60 (odds
ratio (OR) 5.1, 95% CI 2.4-10.8), being married (OR = 2.5, 95% CI 1.0-6.0), and the
absence of peripheral vascular disease (OR = 5.4, 95% CI 1.8-16.5). 22% of patients had
residual angina at 1 year. Patients without angina (SAQ Angina Frequency score =100
vs. <100) at 1-year were significantly more likely to be working compared to patients with
residual angina (OR=2.5, 95% CI 1.2-5.4, p=0.015).
Conclusions: Improvement in angina as measured by the SAQ was significantly
assocaited with returning to work following PCI. Patients who are married, younger (less
than 60), without peripheral vascular disease are also more likely to return to work.
1138-46 Time-Course of Healing Responses After Intracoronary 
Photodynamic Therapy in Porcine Coronary Arteries
Ian Leitch, John Roessler, Joe Stalder, Steve Rychnovsky, Rufus Seabron, Robert Scott, 
Ron Waksman, Washington Hospital Center, Washington, DC, Miravant Medical 
Technologies, Inc., Santa Barbara, CA
Background: Intracoronary PhotoPoint® photodynamic therapy (PDT) holds promise in
coronary artery disease for treating atherosclerotic vulnerable plaque and restenosis. We
have previously demonstrated that intracoronary PDT with the novel photosensitizer
drugs, MV0611 and MV0633, significantly inhibits neointima formation 14 days after bal-
loon injury in porcine coronary arteries. However, the temporal biological effects and
long-term arterial healing responses following intracoronary PDT are unknown. There-
fore, we have assessed the vascular effects and time-course for complete healing of
swine coronary arteries after intracoronary PDT.
Methods: Normolipidemic swine (n=22) were injected with photosensitizer (MV0611 or
MV0633; 3 mg/kg iv; Miravant, CA) and 4 hrs later the coronary arteries were illuminated
with light (125 J/cm2) using an endovascular catheter (3 x 30 mm; Miravant), to cause
photo-selective targeting of PDT to the vessel wall. Controls consisted of drug or light
alone. Arteries were assessed by histology at 3, 14, 30, 60 or 90 days post-PDT for
smooth muscle cell (SMC) content and re-endothelialization.
Results: All control or PDT arteries were patent at follow-up with no evidence of throm-
bosis, degeneration, or aneurysm formation. At 3 days, medial SMC’s were dramatically
reduced in PDT arterial sections, 1261 ± 397 cells/mm2 versus controls 3863 ± 109 cells/
mm2 (p < 0.001), with an absence of endothelial cells. By 14 days after PDT, SMC’s had
significantly repopulated the media (PDT: 2661 ± 124 cells/mm2 vs controls: 3701 ± 256
cells/mm2; p < 0.01) and a maximal re-endothelialization score was observed. At 30
days, medial SMC re-population was complete and at 30-90 days there were no differ-
ences in cellular populations in PDT arteries versus controls.
Conclusion: These results provide an insight into the temporal healing responses of cor-
onary arteries after intracoronary PhotoPoint PDT. Long-term normalization and stabili-
zation of the arterial wall following PhotoPoint PDT may represent a potential beneficial
aspect of this novel treatment for atherosclerotic vulnerable plaque and restenosis.
1138-63 The Impact of Ejection Fraction on Long-Term Mortality 
After Revascularization in Patients With Congestive 
Heart Failure: A Report From the BARI Trial
Elizabeth M. Holper, David P. Faxon, Maria Mori Brooks, Lauren J. Kim, Katherine M. 
Detre, University of Chicago, Chicago, IL, University of Pittsburgh, Pittsburgh, PA
Background: Congestive heart failure (CHF) has been associated with worse outcomes
for patients undergoing PTCA and CABG. The impact of low versus normal ejection frac-
tion (EF) on long-term mortality after revascularization among patients with CHF has not
been studied. Methods: The patients in the Bypass Angioplasty Revascularization Inves-
tigation (BARI) randomized trial and registry cohorts with EF measurements at baseline
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were considered. Patients with CHF and an EF<40% were compared to those with CHF
and an EF>40% and to those with no CHF. The comparison of outcomes was stratified by
diabetes status and revascularization procedure. Results: Among patients with CHF,
those with low EF were significantly younger, less frequently had hypertension, but more
frequently had ECG abnormalities and triple vessel disease compared to those with
EF>40%. 
After adjusting for baseline clinical factors and revascularization procedure, the risk of 
long-term mortality was the greatest in patients with CHF and EF<40% (HR=3.33, 95% 
CI 2.31-4.78, p<0.01), but also significantly higher in patients with CHF and EF>40% 
(HR=1.66, 95% CI 1.31-2.10, p<0.01) than in patients with no CHF. The 9-year survival 
rate of diabetic patients with CHF and a low EF was extremely low at 22%. Conclusion: 
Among CHF patients undergoing revascularization, both low and normal EF significantly 
predict long-term survival. The absolute effect of CHF and low EF appears to be particu-
larly important among patients with diabetes.
1138-64 Major Reduction in Adverse Outcomes of Patients With 
Congestive Heart Failure Undergoing Percutaneous 
Coronary Intervention: A Comparison of the National 
Heart, Lung, and Blood Institute 1985-1986 
Percutaneous Transluminal Coronary Angioplasty 
Registry and the Current Dynamic Registry
Elizabeth M. Holper, David P. Faxon, Alice K. Jacobs, David O. Williams, Paul Coady, 
Faith Selzer, Helen Vlachos, Katherine M. Detre, The University of Chicago, Chicago, IL, 
The University of Pittsburgh, Pittsburgh, PA
Background: Percutaneous coronary intervention (PCI) in patients with a history of con-
gestive heart failure (CHF) has been associated with worse outcomes. However, little is
know about these outcomes in the current era of improved CHF therapy and the wide-
spread use of coronary stents. Methods: Utilizing patients from the NHLBI 1985-1986
PTCA Registry and the Dynamic Registry (recruitment waves: 1997-1988, 1999 and
2001), we investigated differences in baseline risk factors, and acute and 1-year out-
comes in non-acute myocardial infarction patients with CHF undergoing their first PCI
during two different eras. This study sample is comprised of 117 CHF patients from the
1985-1986 PTCA Registry and 257 CHF patients enrolled in the Dynamic Registry.
Results: Compared to the 85-86 Registry, patients in the Dynamic Registry with CHF
were significantly older and had a higher prevalence of diabetes, prior CABG , triple ves-
sel CAD, and a lower mean EF, but had a higher lesion success rate after PTCA (92.6%
vs. 70.9%, p<0.001). In the Dynamic registry, stents were used in 77% of patients, and
there was a significantly higher use of ace inhibitors, aspirin, beta blockers, and statins.
The odds and risk ratios of adverse events in the Dynamic compared to PTCA registries
follow: 
Conclusions: While patients with CHF undergoing PCI in the current era have more
comorbidities and a lower EF, the in-hospital and long-term outcomes are markedly
improved. This is likely due to improved procedural success and improved medical ther-
apy.
1138-65 Identification of Risk Factors for In-Hospital 
Complications in Patients With Severe Left Ventricular 
Dysfunction Undergoing Percutaneous Coronary 
Intervention
Anjli Maroo, W. H. Wilson Tang, Gary S. Francis, Stephen G. Ellis, Cleveland Clinic 
Foundation, Cleveland, OH
Background: Although coronary artery bypass graft surgery is often used to treat
patients with ischemic cardiomyopathy (ICM) and severe left ventricular systolic dysfunc-
tion (LVSD), data regarding percutaneous coronary intervention (PCI) with coronary
stenting in this high-risk patient population are very limited.
Methods: We retospectively evaluated consecutive patients with ICM and severe LVSD
(ejection fraction </= 35%) who underwent PCI with coronary stenting between 1/1/1995
and 12/30/2002. Patients with acute myocardial infarction (MI) were excluded. We com-
pared the frequency of in-hospital complications (in-hospital death, post-PCI MI, and
emergent CABG) in patients with severe LVSD (n=1274) and in patients with normal
LVEF (>/=50%) (n=6282) by univariate analysis. Predictors of in-hospital complications in
patients with severe LVSD were determined by multivariable logistic regression analysis.
Results: Baseline characteristics of patients with severe LVSD included age (68+/-11
years), gender (75% male), LVEF (28+/-7%), diabetes mellitus (39%), prior MI (69%),
and prior CABG (46%). The overall rate of in-hospital complications was higher for
patients with severe LVSD than for patients with normal LVEF (7.9% vs. 5.5%, p<0.001).
For patients with severe LVSD, in-hospital complication rates consisted of 2.2% in-hospi-
tal deaths, 5.9% post-PCI MIs, and 0.4% emergent CABG. Independent predictors of in-
hospital complications included NYHA class IV symptoms, ACC lesion type B2 or C,
renal insufficiency (serum creatinine > 2 mg/dL), and intended SVG intervention (all
p<0.05). In our study, 372 patients with severe LVSD (29%) had none of these risk fac-
tors. In the absence of these 4 risk factors, the in-hospital complication rate for patients
with severe LVSD was 3.5%.
Conclusions: Although patients with severe LVSD have an overall higher risk of in-hos-
pital complications following PCI with stenting, in the absence of several high-risk clinical
features, rates of in-hospital complications in patients with severe LVSD versus average
patients with normal LVEF are comparable.
1138-66 Can Intravascular Ultrasound Guided Cutting Balloon 
Angioplasty Before Stenting Be a Substitute for Drug 
Eluting Stent? Final Results of the Prospective 
Randomized Multicenter Trial Comparing Cutting 
Balloon With Balloon Angioplasty Before Stenting 
(Reduce III)
Yukio Ozaki, Takahiko Suzuki, Tetsu Yamaguchi, Masato Nakamura, Michihiko Kitayama, 
Hideo Nishikawa, Teruo Inoue, Fumihiko Usuba, Kazuhiro Hara, Masami Sakurada, 
Kojiro Awano, Toru Kobayashi, Katsumi Ueno, Mikihiro Kijima, Yasushi Asakura, Sugao 
Ishiwata, Tatsuya Yasukawa, The REDUCE III Study Group, Aichi Med. Univ., Nagakute-
Toyohashi-Tokyo, Japan, Toho Ohashi Hospital, Kanazawa-Ise-Tokyo, Japan
Background: Stent restenosis still occurs even in the drug eluting stent (DES) era.
IVUS-guided cutting balloon angioplasty (CB) before stenting would offer a favorable
long-term outcome similar to DES.
Methods: We randomly assigned 521 anginal patients to either CB before stenting (260
patients) or balloon angioplasty (POBA) before stenting (261 patients). IVUS guided pro-
cedures were performed in 279 (54%) patients. All patients were divided into 4 groups
according to devices before stenting and either IVUS- or Angio-guidance (IVUS-guided
CB-stent; 137 pts, Angio-guided CB-stent; 123 pts, IVUS-guided POBA-stent; 142 pts,
and Angio-guided POBA-stent; 119 pts). The primary angiographic endpoint was rest-
enosis (>50% at follow-up).
Results: Follow-up angiography was performed in 453 patients (87%). An average ves-
sel size was 2.80+0.47mm with no difference among 4 groups (p=ns). IVUS guided CB-
stent indicated the lowest restenosis rate (6.6%) in comparison with Angio-guided CB-
stent (17.9%, p<.01), IVUS-guided POBA-stent (19.8%, p<.01) and Angio-guided POBA-
stent (18.2%, p<.01). Reflecting this phenomenon, overall restenosis rate was signifi-
cantly lower in all CB-stent than all POBA-stent (11.8% versus 19.1%, p<.05). While
baseline vessel area (VA) and lumen area (LA) were similar between the IVUS-CB-stent
and IVUS-POBA-stent groups, LA immediately after CB or POBA before stenting
(5.29+1.61mm2 vs. 4.15+1.33mm2, p<.05), LA after stenting (7.39+2.29mm2 vs.
6.61+2.04mm2, p<.05) and LA at follow-up (5.26+2.82mm2 vs. 4.41+2.05, p<.05) were
consistently greater in IVUS-CB-stent than IVUS-POBA-stent. Multivariate logistic
regression analysis to evaluate the respective contributions of clinical, angiographic and
IVUS variables to restenosis indicated that use of POBA (not CB) before stenting, DM,
LAD lesion and smaller vessel area by IVUS were independent predictors for restenosis.
Conclusions: Greater lumen obtained by IVUS-guided CB could convey a favorable
long-term outcome. While among 4 groups IVUS-guided CB-stent indicated the lowest
restenosis rate (6.6%) similar to those obtained by DES, IVUS-guided CB-stent can be a
substitute for DES in some clinical settings.
Unadjusted 9-Year Survival by EF
No CHF CHF & EF_40% CHF & EF<40% 2-way
p-value
N 9-Yr Survival N 9-Yr Survival N 9-Yr Survival
All patients 2917 82% 167 56% 49 45% 0.07
No Diabetes 2451 84% 103 65% 31 58% 0.31
CABG 1000 85% 43 62% 19 63% 0.57
PTCA 1451 84% 60 67% 12 50% 0.48
Diabetes 466 68% 64 41% 18 22% 0.03
CABG 217 71% 30 52% 8 25% 0.04
PTCA 249 65% 34 32% 10 18% 0.25
In-Hospital Adjusted OR Dynamic vs PTCA Registry CI P Value
Death 0.35 (0.14-0.91) <0.05
CABG 0.09 (0.03-0.34) _0.001
Death/MI/CABG 0.18 (0.09-0.38) _0.001
1-Year Adjusted RR Dynamic vs PTCA Registry CI P Value
CABG 0.26 (0.12-0.56) _0.001
Death/MI/CABG 0.55 (0.36-0.85) <0.01
PCI after discharge/CABG 0.46 (0.28-0.75) <0.01
